Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus

BACKGROUND: Diabetic foot ulcer (DFU) is a dangerous complication of diabetes mellitus (DM), which can lead to the development of chronic wounds and amputations. Recombinant human epidermal growth factor (rhEGF) can be used as an adjuvant treatment for chronic wounds resistant to standard treatment....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. L. Zaitseva, V. M. Zhilyaev, G. R. Galstyan
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	diabetes mellitus diabetic foot ulcer epidermal growth factor chronic wounds Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/afaa240d7d314e32929dc0145372ede3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:afaa240d7d314e32929dc0145372ede3
record_format	dspace
spelling	oai:doaj.org-article:afaa240d7d314e32929dc0145372ede32021-11-14T09:00:23ZLong-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus2072-03512072-037810.14341/DM12701https://doaj.org/article/afaa240d7d314e32929dc0145372ede32021-02-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12701https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGROUND: Diabetic foot ulcer (DFU) is a dangerous complication of diabetes mellitus (DM), which can lead to the development of chronic wounds and amputations. Recombinant human epidermal growth factor (rhEGF) can be used as an adjuvant treatment for chronic wounds resistant to standard treatment. Studies have demonstrated its clinical efficacy, however, there is insufficient information on the long-term results of treatment, its safety and the effect on the progression of diabetes complications, adverse cardiovascular events and the development of cancer.AIM: To assess the long-term results of rhEGF therapy for trophic foot ulcers in individuals with multiple complications of diabetes.METHODS: The study included 20 patients with type 1 and type 2 diabetes and various forms of DFS without critical ischemia, who had previously been treated with DFS using rhEGF in order to assess the general condition, progression of microand macrovascular complications of diabetes, adverse cardiovascular events, the development of cancer and the quality of life.RESULTS: There was a statistically significant difference between the area of wound defects, the percentage of granulation tissue that filled the wound defect, before the start of rhEGF treatment and at the time of discharge from the hospital (p <0.05). During treatment with rhEGF, mild adverse events were observed in 35%. Complete epithelialization of wounds in most patients occurred in 3 [2; 4] months. In 11.76%, the wound was not completely epithelialized. Relapse occurred in 5.8% due to non-compliance with limb unloading. Minor amputation was performed in 1 patient. Progression of diabetic retinoand nephropathy was revealed in 23.5%. 11.76% suffered myocardial infarction of unknown age, 1 patient (5.88%) suffered acute cerebrovascular accident. Serious adverse events in the form of PE with a fatal outcome and critical ischemia of the lower limb were recorded in 5.8%.CONCLUSIONS: As a result of the study of long-term results of rhEGF treatment of chronic foot wounds, a low percentage of relapses and small amputations, the absence of high amputations and oncological diseases, the development of serious adverse events in 2 patients, the progression of diabetic retinoand nephropathy in 4 patients, the development of IM of unknown age in 2 patients was recorded. and stroke in 1 patient after rhEGF therapy.E. L. ZaitsevaV. M. ZhilyaevG. R. GalstyanEndocrinology Research Centrearticlediabetes mellitusdiabetic foot ulcerepidermal growth factordiabetic foot ulcerchronic woundsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 6, Pp 532-540 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus diabetic foot ulcer epidermal growth factor diabetic foot ulcer chronic wounds Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus diabetic foot ulcer epidermal growth factor diabetic foot ulcer chronic wounds Nutritional diseases. Deficiency diseases RC620-627 E. L. Zaitseva V. M. Zhilyaev G. R. Galstyan Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
description	BACKGROUND: Diabetic foot ulcer (DFU) is a dangerous complication of diabetes mellitus (DM), which can lead to the development of chronic wounds and amputations. Recombinant human epidermal growth factor (rhEGF) can be used as an adjuvant treatment for chronic wounds resistant to standard treatment. Studies have demonstrated its clinical efficacy, however, there is insufficient information on the long-term results of treatment, its safety and the effect on the progression of diabetes complications, adverse cardiovascular events and the development of cancer.AIM: To assess the long-term results of rhEGF therapy for trophic foot ulcers in individuals with multiple complications of diabetes.METHODS: The study included 20 patients with type 1 and type 2 diabetes and various forms of DFS without critical ischemia, who had previously been treated with DFS using rhEGF in order to assess the general condition, progression of microand macrovascular complications of diabetes, adverse cardiovascular events, the development of cancer and the quality of life.RESULTS: There was a statistically significant difference between the area of wound defects, the percentage of granulation tissue that filled the wound defect, before the start of rhEGF treatment and at the time of discharge from the hospital (p <0.05). During treatment with rhEGF, mild adverse events were observed in 35%. Complete epithelialization of wounds in most patients occurred in 3 [2; 4] months. In 11.76%, the wound was not completely epithelialized. Relapse occurred in 5.8% due to non-compliance with limb unloading. Minor amputation was performed in 1 patient. Progression of diabetic retinoand nephropathy was revealed in 23.5%. 11.76% suffered myocardial infarction of unknown age, 1 patient (5.88%) suffered acute cerebrovascular accident. Serious adverse events in the form of PE with a fatal outcome and critical ischemia of the lower limb were recorded in 5.8%.CONCLUSIONS: As a result of the study of long-term results of rhEGF treatment of chronic foot wounds, a low percentage of relapses and small amputations, the absence of high amputations and oncological diseases, the development of serious adverse events in 2 patients, the progression of diabetic retinoand nephropathy in 4 patients, the development of IM of unknown age in 2 patients was recorded. and stroke in 1 patient after rhEGF therapy.
format	article
author	E. L. Zaitseva V. M. Zhilyaev G. R. Galstyan
author_facet	E. L. Zaitseva V. M. Zhilyaev G. R. Galstyan
author_sort	E. L. Zaitseva
title	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
title_short	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
title_full	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
title_fullStr	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
title_full_unstemmed	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
title_sort	long-term follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/afaa240d7d314e32929dc0145372ede3
work_keys_str_mv	AT elzaitseva longtermfollowupoftreatmentofchronicfootwoundswithrecombinanthumanepidermalgrowthfactorinpatientswithdifferentcomplicationsofdiabetesmellitus AT vmzhilyaev longtermfollowupoftreatmentofchronicfootwoundswithrecombinanthumanepidermalgrowthfactorinpatientswithdifferentcomplicationsofdiabetesmellitus AT grgalstyan longtermfollowupoftreatmentofchronicfootwoundswithrecombinanthumanepidermalgrowthfactorinpatientswithdifferentcomplicationsofdiabetesmellitus
_version_	1718429482868539392

Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus

Ejemplares similares